Ainos, Inc. reported its financial results for the second quarter and first half of 2025, revealing a revenue of $4,663 for Q2 2025, a significant increase from zero revenue in the same period last year. For the first half of 2025, the company generated $110,870 in revenue, compared to $20,729 in the first half of 2024, marking a 435% increase. The cost of revenues decreased to $937 in Q2 2025 from $25,373 in Q2 2024, contributing to a gross profit of $3,726, a turnaround from a gross loss of $25,373 in the prior year. However, the company reported a net loss of $4,084,990 for Q2 2025, up 28% from a net loss of $3,195,022 in Q2 2024.
In terms of operational changes, Ainos has undergone a reverse stock split at a ratio of 1-for-5, effective June 30, 2025, to comply with Nasdaq listing requirements. This adjustment increased the number of shares issued and outstanding to 4,267,990. The company also reported a total stockholders' equity of $11,442,786 as of June 30, 2025, down from $15,516,310 at the end of 2024, primarily due to accumulated losses. The company’s cash and cash equivalents decreased to $1,223,184 from $3,892,919 at the end of 2024, reflecting ongoing operational expenditures.
Ainos has focused on advancing its AI Nose technology platform, which integrates gas sensors with a proprietary algorithm for scent digitization. The company is expanding its applications beyond healthcare into industrial and robotics sectors, with strategic partnerships aimed at deploying AI Nose across various environments. The company has also initiated a subscription-based model, SmellTech-as-a-Service, to enhance its revenue streams. Additionally, Ainos is progressing with its VELDONA oral interferon therapeutics, targeting rare diseases, and plans to enter clinical trials in Taiwan for two lead indications.
The company’s operational metrics indicate a continued investment in research and development, with R&D expenses totaling $1,911,800 in Q2 2025, slightly down from $1,978,756 in Q2 2024. Selling, general, and administrative expenses rose significantly to $1,837,613, reflecting increased share-based compensation. Ainos anticipates ongoing losses as it invests in product development and market expansion, with a net loss of $7,371,012 for the first half of 2025, compared to $6,509,832 in the same period last year. The company plans to finance its operations through existing cash reserves and potential equity or debt financing, although it acknowledges the uncertainty surrounding future funding availability.
About Ainos, Inc.
Ainos, Inc. is a diversified healthcare company specializing in novel point-of-care testing (POCT), low-dose interferon alpha therapeutics (VELDONA), and synthetic RNA-based preventative medicine. Its product portfolio includes VELDONA Pet supplements and AI-powered VOC sensing POCT devices for rapid, non-invasive health diagnostics. Operating primarily in Taiwan, Ainos leverages outsourced manufacturing and global distribution partnerships to develop affordable, telehealth-friendly healthcare solutions targeting human and animal health markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.